This is a First-in-Human, single arm, open-label, multi-national study designed to determine the safety, tolerability and preliminary efficacy of MCLA 117.

Start Date01 Apr 2016

Sponsor / Collaborator

Merus NV

100 Clinical Results associated with Tepoditamab

100 Translational Medicine associated with Tepoditamab

100 Patents (Medical) associated with Tepoditamab

Literatures (Medical) associated with Tepoditamab

03 Jul 2019·Expert Opinion on Biological TherapyQ3 · MEDICINE

MCLA-117, a CLEC12AxCD3 bispecific antibody targeting a leukaemic stem cell antigen, induces T cell-mediated AML blast lysis

Q3 · MEDICINE

Article

Author: Logtenberg, Ton ; Hendriks, Linda J. A. ; de Kruif, John ; Gibbins, John D. ; Leenders, Marij ; Dolstra, Harry ; Hangalapura, Basav N. ; van Loo, Pieter Fokko ; Thordardottir, Soley ; Bakker, Alexander B. H. ; Roovers, Rob C. ; Throsby, Mark ; Veninga, Henrike ; Sirulnik, Andres ; Kramer, Arjen ; Doornbos, Robert P.

Objective: We report the characterization of MCLA-117, a novel T cell-redirecting antibody for acute myeloid leukaemia (AML) treatment targeting CD3 on T cells and CLEC12A on leukaemic cells. In AML, CLEC12A is expressed on blasts and leukaemic stem cells. Methods: The functional capacity of MCLA-117 to redirect resting T cells to eradicate CLEC12A^POS tumor cells was studied using human samples, including primary AML samples. Results: Within the normal hematopoietic compartment, MCLA-117 binds to cells expressing CD3 and CLEC12A but not to early myeloid progenitors or hematopoietic stem cells. MCLA-117 induces T cell activation (EC₅₀ = 44 ng/mL), T cell proliferation, mild pro-inflammatory cytokine release, and redirects T cells to lyse CLEC12A^POS target cells (EC₅₀ = 68 ng/mL). MCLA-117-induced targeting of normal CD34^POS cells co-cultured with T cells spares erythrocyte and megakaryocyte differentiation as well as preserves mono-myelocytic lineage development. In primary AML patient samples with autologous T cells, MCLA-117 robustly induced AML blast killing (23-98%) at low effector-to-target ratios (1:3-1:97). Conclusion: These findings demonstrate that MCLA-117 efficiently redirects T cells to kill tumour cells while sparing the potential of the bone marrow to develop the full hematological compartment and support further clinical evaluation as a potentially potent treatment option for AML.

100 Deals associated with Tepoditamab

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acute Myeloid Leukemia	Phase 1	FR	Merus NV	01 Apr 2016
Acute Myeloid Leukemia	Phase 1	BE	Merus NV	01 Apr 2016
Acute Myeloid Leukemia	Phase 1	NL	Merus NV	01 Apr 2016
Acute Myeloid Leukemia	Phase 1	US	Merus NV	01 Apr 2016
Acute Myeloid Leukemia	Phase 1	IT	Merus NV	01 Apr 2016
Myelodysplastic Syndromes	Phase 1	NL	Merus NV	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis